Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE, Ablation, and Durvalumab in Intermediate HCC (TAD)
NCT04517227Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jul 2021
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 2 trial of durvalumab in hepatocellular carcinoma (HCC), sponsored by Fudan University. Status: unknown.
02
Drugs
durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04517227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04517227.